中国现代医生杂志欢迎您.   今天是:          
张 瑜1 路青华1 曹海芳1 张生荣2.恩替卡韦联合干扰素治疗乙肝肝硬化的临床效果及对肝纤维化和细胞免疫功能的影响[J].中国现代医生,2021,59(23):83-86
恩替卡韦联合干扰素治疗乙肝肝硬化的临床效果及对肝纤维化和细胞免疫功能的影响
Clinical effect of entecavir and entecavir combined with interferon in the treatment of hepatitis B cirrhosis and its influence on liver fibrosis and cellular immune function
  
DOI:
中文关键词:  恩替卡韦  干扰素  乙肝肝硬化  肝纤维化  细胞免疫功能
英文关键词:Entecavir  Interferon  Hepatitis B cirrhosis  Liver fibrosis  Cellular immune function
基金项目:
作者单位
张 瑜1 路青华1 曹海芳1 张生荣2 1.青海省第四人民医院肝病一科青海西宁 8100002.青海省第四人民医院科教科青海西宁 810000 
摘要点击次数: 157
全文下载次数: 709
中文摘要:
      目的 探讨恩替卡韦联合干扰素治疗乙肝肝硬化的临床效果及对肝纤维化和细胞免疫功能的影响。方法 选择2018年2月至2020年8月我院收治的105例患者,随机分为观察组(n=53)和对照组(n=52)。对照组采用恩替卡韦治疗,观察组在此基础上联合干扰素治疗。观察比较两组临床疗效,HA、LN、PCⅢ、CⅣ等肝纤维化指标,CD4+、CD8+、CD4+/CD8+等细胞免疫功能指标。结果 观察组整体临床疗效优于对照组,差异有统计学意义(Z=5.157,P=0.000);临床总有效率为94.34%,明显高于对照组的78.85%,差异有统计学意义(χ2=5.453,P=0.020)。治疗后,两组HA、LN、PCⅢ、CⅣ水平较治疗前均下降(P<0.05),且观察组各项指标水平均显著低于对照组,差异有统计学意义(P=0.000)。治疗后两组CD4+、CD4+/CD8+水平较治疗前升高(P<0.05),且观察组CD4+、CD4+/CD8+水平均显著高于对照组,差异有统计学意义(t=5.406,P=0.000;t=8.021,P=0.000)。结论 恩替卡韦联合干扰素治疗乙肝肝硬化临床疗效显著,可有效延缓肝纤维化进程,提高机体细胞免疫功能,延缓疾病进程,值得推广应用。
英文摘要:
      Objective To investigate the clinical effect of entecavir and entecavir combined with interferon in the treatment of hepatitis B cirrhosis and the influence on liver fibrosis and cellular immune function.Methods A total of 105 patients admitted to our hospital from February 2018 to August 2020 were selected as the research subjects and randomly divided into the observation group(n=53) and the control group(n=52).The control group was treated with entecavir,while the observation group was treated with interferon on this basis of entecavir treatment.The clinical efficacy,indicators of liver fibrosis (such as HA,LN,PCⅢand CⅣ),and indicators of cellular immune function (such as CD4+,CD8+ and CD4+/CD8+) of the two groups were observed and compared.Results The overall clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant (Z=5.157,P=0.000);the total clinical effective rate was 94.34%,which was significantly higher than that in the control group(78.85%),and the difference was statistically significant (χ2=5.453,P=0.020).After treatment,the levels of HA,LN,PCⅢ,and CⅣin the two groups decreased more obviously than before treatment (P<0.05),and the levels of various indicators in the observation group were significantly lower than those in the control group,and the difference was statistically significant (P=0.000).After treatment,the levels of CD4+ and CD4+/CD8+ in the two groups increased more obviously than before treatment (P<0.05),and the levels of CD4+and CD4+/CD8+in the observation group were significantly higher than those in the control group,and the difference was statistically significant (t=5.406,P=0.000;t=8.021,P=0.000).Conclusion The combination of entecavir and interferon has a significant clinical effect in the treatment of hepatitis B cirrhosis.It can effectively delay the process of liver fibrosis and the disease process,and improve the body′s cellular immune function.Therefore,it is worthy of popularization and application.
查看全文  查看/发表评论  下载PDF阅读器
关闭
    • 关键词 :
    • 中国医生
    • 中国现代医生
    • 中国临床医生
    • 中国医师
    • 主任医师
    • 中国医学
    • 中华医学
    • 中国医院
    • 中国医药
    • 中国医疗
    • 现代医生
    • 现代医学
    • 现代医药
    • 现代医院
    • 现代药物
    • 现代护理
    • 现代临床
    • 医学杂志
    • 药学杂志
    • 医药杂志
    • 医生杂志
    • 医师杂志
    • 医疗杂志
    • 医药期刊
    • 医学期刊
    • 医药卫生期刊
    • 医药论文
    • 医学论文
    • 科研论文
    • 职称论文
    function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=3C06DB566315F8DC786D8F01EA4720E032A420223E88AC0037229E98025C66DDCE79BB23233274F8764A38E69427D230534EC1792A811743F3BCDE7CDEF15A855BF4CB21EF68FB97C5579BD726E3419DD3617A076C7EC041BA083A83A7F6CCA6F5B40EA348BB973BE1B2BBF6178254F646975A9A6B52441EB769E48C7B057294179F26A570A0602380CA2E016C0F5173DE91ACA28CAEA069457C29AC744E9B5A3FD76C43EF049C66E72F9DF12439E352&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=8EDAEC11C165015425CEEA15366CB0A7&yid=9475FABC7A03F4AB&aid=&vid=&iid=EA389574707BDED3&sid=06EA2770E96C5402&eid=7AA74D31F1FF2DCE&fileno=2022853&flag=1&is_more=0">